Work

Down syndrome regression disorder responsive to immunoglobulin modulation therapy

Year: 2026
Type: article
Study design: Case Report
Abstract: Down syndrome (DS), caused by trisomy 21 in ~95% of cases, carries three copies of the chromosome 21 interferon receptor cluster (IFNAR1, IFNAR2, IFNGR2, and IL10RB), leading to a constitutive, mild interferonopathy across types I, II, and III signalling. Down syndrome regression disorder (DSRD) is a devastating neuro-regression occurring between 10 and 30 years. A sub-group shares immunological and neuroimaging features with the monogenic type I interferonopathies, though the mechanism differs: trisomy 21 confers receptor-level over-responsiveness rather than ligand excess. DSRD remains a diagnosis of exclusion but commonly arises on a background of pre-existing neurodevelopmental or neuropsychiatric comorbidity, so identifying a comorbidity does not itself exclude it. Both adolescents described here presented with severe neuropsychiatric regression, symmetric basal ganglia mineralization, and an isolated elevation of the interferon-stimulated gene IFI27. No commissioning pathway for DSRD immune-directed therapy exists in the United Kingdom (UK). Approximately 21 months after onset, intravenous immunoglobulin (IVIG) was commenced in both, for the first time in the UK: 2 g/kg loading then eight monthly doses of 1 g/kg. Nine doses produced partial but clinically meaningful multidomain improvement without serious adverse events. Serial IFI27 fell in both but remained above the reference interval throughout; it did not track clinical response. These descriptive observations require confirmation in controlled studies. Inability to access workup and treatment is a health inequity; early recognition and a multidisciplinary approach spanning neurology, psychiatry, and immunology are needed.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236767680
FWCI:
Cites: 38
Cited by:
Related to: 10
Parts: 1